Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Historic Change in Acquisitions & Divestments for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q4 2024 value amounting to $10.2 million.

  • Xeris Biopharma Holdings' Change in Acquisitions & Divestments fell 3176.0% to $10.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 7725.33%. This contributed to the annual value of $40.2 million for FY2024, which is 59.0% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Change in Acquisitions & Divestments stood at $10.2 million for Q4 2024, which was down 3176.0% from $15.0 million recorded in Q3 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Acquisitions & Divestments registered a high of $34.6 million during Q1 2021, and its lowest value of $5.0 million during Q1 2024.
  • Its 5-year average for Change in Acquisitions & Divestments is $14.8 million, with a median of $11.3 million in 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Change in Acquisitions & Divestments crashed by 8066.38% in 2022 and then skyrocketed by 11786.49% in 2023.
  • Xeris Biopharma Holdings' Change in Acquisitions & Divestments (Quarter) stood at $17.8 million in 2020, then crashed by 41.14% to $10.5 million in 2021, then decreased by 11.43% to $9.3 million in 2022, then surged by 61.29% to $15.0 million in 2023, then tumbled by 31.76% to $10.2 million in 2024.
  • Its Change in Acquisitions & Divestments was $10.2 million in Q4 2024, compared to $15.0 million in Q3 2024 and $10.0 million in Q2 2024.